Please login to the form below

Not currently logged in
Email:
Password:

axi-cel

This page shows the latest axi-cel news and features for those working in and with pharma, biotech and healthcare.

New trial results suggest CAR-T effects are durable in lymphoma

New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts. ... Celgene and Juno are hoping to crash the party soon with their

Latest news

  • Gilead makes $11.9bn play for CAR-T specialist Kite Gilead makes $11.9bn play for CAR-T specialist Kite

    At a stroke, Gilead becomes a front-runner in the race to bring the first CAR-T to market with Novartis, claiming Kite's late-stage candidate axicabtagene ciloleucel (axi-cel ... Kite also has a pipeline of other CAR-T therapies following behind axi-cel,

  • Kite starts EU trial of lead CAR-T therapy Kite starts EU trial of lead CAR-T therapy

    Kite Pharma has treated its first European patient with axicabtagene ciloleucel (KTE-C19 or axi-cel), its CAR-T therapy for B-cell lymphomas. ... The start of the trial comes after Kite has already filed for approval of axi-cel in the EU based on the

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Headline. $m. Kite (US). Gilead (US). Company acquisition. CAR-T technology with lead product ‘axi-cel’ under priority review at the FDA for treatment of refractory aggressive NHL.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...